
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

Under the Securities Exchange Act of 1934
(Amendment No. 1)

IMMATICS N.V.
(Name of Issuer)

Ordinary shares, nominal value €0.01 per share
(Title of Class of Securities)

N44445109
(CUSIP Number)

December 31, 2021
(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Name of Reporting Persons dievini Hopp BioTech holding GmbH & Co. KG	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) OO	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons DH-LT-Investments GmbH	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 726,282 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 726,282 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 726,282 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 1.2% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) OO	

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.
- (2) Represents 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.
- (3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons DH-Capital GmbH & Co. KG	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares common shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) OO	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons OH Beteiligungen GmbH & Co. KG	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) OO	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Dietmar Hopp	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Oliver Hopp	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Daniel Hopp	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽²⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽³⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Prof. Dr. Friedrich von Bohlen und Halbach	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares ⁽³⁾	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3% ⁽⁵⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Prof. Dr. Christof Hettich	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3 ⁽³⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

1.	Name of Reporting Persons Dr. Mathias Hothum	
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) <input type="checkbox"/> (b) <input type="checkbox"/> ⁽¹⁾	
3.	SEC USE ONLY	
4.	Citizenship or Place of Organization Germany	
Number of Shares Beneficially Owned by Each Reporting Person With:	5.	Sole Voting Power 0 ordinary shares
	6.	Shared Voting Power 17,202,355 ordinary shares ⁽²⁾
	7.	Sole Dispositive Power 0 ordinary shares
	8.	Shared Dispositive Power 17,202,355 ordinary shares ⁽²⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 17,202,355 ordinary shares	
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/>	
11.	Percent of Class Represented by Amount in Row (9) 27.3 ⁽³⁾	
12.	Type of Reporting Person (See Instructions) IN	

(1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Represents 16,476,073 shares held of record by dievini and 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

(3) This percentage is calculated based on 62,909,231 shares of the Issuer’s ordinary shares reported to be outstanding by the Issuer in its Form F-3 Registration Statement filed with the Securities and Exchange Commission on August 2, 2021.

Introductory Note: This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments, GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”) in respect of ordinary shares of Immatix N.V.

Item 1(a) Name of Issuer:

Immatix N.V.

Item 1(b) Address of Issuer’s principal executive offices:

Paul-Ehrlich-Straße 15
72076 Tübingen, Germany

Items 2(a) Name of Reporting Persons filing:

dievini Hopp BioTech holding GmbH & Co. KG (“dievini”)
DH-LT-Investments GmbH (“DH-LT-Investments”)
DH-Capital GmbH & Co. KG (“DH-Capital”)
OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”)
Dietmar Hopp
Oliver Hopp
Daniel Hopp
Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”)
Prof. Dr. Christof Hettich (“Dr. Hettich”)
Dr. Mathias Hothum (“Dr. Hothum”)

Item 2(b) Address or principal business office or, if none, residence:

The address of the principal business office of dievini, DH-LT Investments, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Heidelberger Straße 43, 69168 Wiesloch, Germany.

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

Item 2(c) Citizenship:

Name	Citizenship or Place of Organization
Dievini	Germany
DH-Capital	Germany
OH Beteiligungen	Germany
Dietmar Hopp	Germany
Oliver Hopp	Germany
Daniel Hopp	Germany
Dr. von Bohlen	Germany
Dr. Hettich	Germany
Dr. Hothum	Germany
DH-LT Investments	Germany

Item 2(d) Title of class of securities:

Ordinary shares, nominal value €0.01 per share.

Item 2(e) CUSIP No.:

N44445109

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

Not applicable.

Item 4 Ownership

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

Item 6 Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8 Identification and Classification of Members of the Group

Not applicable.

Item 9 Notice of Dissolution of Group

Not applicable.

Item 10 Certifications

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2022

DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

DH-CAPITAL GMBH & CO. KG

By: DH Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact

DIETMAR HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

DANIEL HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact

CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact

MATHIAS HOTHUM

DH-LT INVESTMENTS GMBH

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

Exhibit(s):

1 – [Power of Attorney](#)

2 – [Joint Filing Statement](#)

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS that each of the undersigned hereby constitutes and appoints Dr. Marc Hauser, Dr. Christina Eschenfelder and Dr. Moritz Weber of RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB, Harrlachweg 4, 68163 Mannheim, signing individually, the undersigned's true and lawful attorneys-in-fact and agents with respect to the undersigned's holdings of and transactions in securities issued by AC Immune, CureVac N.V., and immatics M.V. (each, a "Company") to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") filings pursuant to Section 13 (Schedule 13D and Schedule 13G), as applicable (including any amendments, exhibits, joint filing agreements or other documents related thereto or in connection therewith) with respect to the securities of the Company in accordance with Section 13 of Securities Exchange Act of 1934, as amended (the "Exchange Act") and any and all rules and regulations thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Schedule 13D and Schedule 13G, as applicable (including any amendments, exhibits, joint filing agreements or other documents related thereto or in connection therewith) and file the same with the SEC and any stock exchange, self-regulatory association or any other authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 13 of the Exchange Act and the rules and regulations thereunder.

This Power of Attorney shall remain in full force and effect until the earlier of (i) the undersigned is no longer required to file such forms with respect to the undersigned's holdings of and transactions in securities issued by the Company or (ii) or until such time as the person or persons to whom power of attorney has been hereby granted cease(s) to perform the function in connection with which he/she was appointed attorney-in-fact or to be an employee of RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB or one of its affiliates, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in fact.

[Signatures on Following Page]

IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 21st day of August, 2020.

DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser*
Name: Dietmar Hopp
Title: Managing Director

By: Dr. Marc Hauser*
Name: Mathias Hothum
Title: Managing Director

DH-CAPITAL GMBH & CO. KG

By: BW Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser*
Name: Dietmar Hopp
Title: Managing Director

OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH
its General Partner

By: Dr. Marc Hauser*
Name: Oliver Hopp
Title: Managing Director

DH-LT-INVESTMENTS GMBH

By: /s/ Dr. Marc Hauser*
Name: Dr. Marc Hauser
Title: Authorized Attorney-in-Fact

/s/ Dr. Marc Hauser*

DIETMAR HOPP

/s/ Dr. Marc Hauser*

OLIVER HOPP

/s/ Dr. Marc Hauser*

DANIEL HOPP

/s/ Dr. Marc Hauser*

CHRISTOF HETTICH

/s/Dr. Marc Hauser*

FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser*

MATHIAS HOTHUM

* Pursuant to separate power of attorney to be filed by amendment

JOINT FILING STATEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Immatix N.V. and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Each party to this Joint Filing Agreement agrees that this Joint Filing Agreement may be signed in counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, each of the undersigned has caused this Joint Filing Agreement to be executed as of this 7th day of February, 2022.

DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

DH-CAPITAL GMBH & CO. KG

By: BW Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH
its General Partner

By: /s/ Dr. Marc Hauser
Name: Dr. Marc Hauser
Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact

DIETMAR HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

DANIEL HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact

CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact

MATHIAS HOTHUM

DH-LT INVESTMENTS GMBH

By: /s/ Dr. Marc Hauser, as attorney-in fact
Name: Dr. Marc Hauser
Title: Attorney-in-Fact